Matches in Nanopublications for { ?s ?p "[In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP939016.RA1QCXD-sQufyOn8xBR7EuJ3F_blH_FRfD66D5pN-jGXw130_assertion description "[In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP939016.RA1QCXD-sQufyOn8xBR7EuJ3F_blH_FRfD66D5pN-jGXw130_provenance.
- NP292883.RA6D1-OR2Wogybotm1l2McPxTkn5bEEyaeyZn2M6c_D5E130_assertion description "[In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP292883.RA6D1-OR2Wogybotm1l2McPxTkn5bEEyaeyZn2M6c_D5E130_provenance.
- assertion description "[In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP433521.RAFGQih9_jgWddMucAemVRFuaN2p-gQstzA9nVr3Rfvw4130_assertion description "[In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP433521.RAFGQih9_jgWddMucAemVRFuaN2p-gQstzA9nVr3Rfvw4130_provenance.
- assertion description "[In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1053461.RAhwrZV7Pto-vRzmg1hJHrMaZzDxTJXip3M18fQ3njChI130_assertion description "[In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053461.RAhwrZV7Pto-vRzmg1hJHrMaZzDxTJXip3M18fQ3njChI130_provenance.
- NP1053462.RAv2V2DRJSOsRwzi1gwmrRwQr6D_UYpYZElcsKY1vp9D0130_assertion description "[In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053462.RAv2V2DRJSOsRwzi1gwmrRwQr6D_UYpYZElcsKY1vp9D0130_provenance.